![Despite 23andMe Authorization, FDA Cautious About PGx Testing](https://www.g2intelligence.com/wp-content/uploads/2023/04/56181_G2_stock_-1080x675.jpg)
Despite 23andMe Authorization, FDA Cautious About PGx Testing
...
...
From - Diagnostic Testing & Emerging Technologies
Several recent U.S. Food and Drug Administration (FDA) actions are bringing point-of-care (POC) infectious disease tests closer to…
From - Diagnostic Testing & Emerging Technologies
Variant reclassification following hereditary cancer genetic testing is common, according to a study published by…
...
From - Diagnostic Testing & Emerging Technologies
The health care technology company Concert Genetics (formerly NextGxDx; Nashville, Tenn.) recently released its third edition of…